Cite
HARVARD Citation
Cortellini, A. et al. (2021). Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. European journal of cancer. pp. 24-35. [Online].